文献速递核素与放射性配体治疗放射性药物与辐射防护

重组α1-微球蛋白或可成为177Lu-奥曲肽治疗中的肾脏保护剂

Recombinant α1-Microglobulin Is a Potential Kidney Protector in 177Lu-Octreotate Treatment of Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2019-03-29

该研究在GOT2和GOT1肿瘤荷瘤小鼠中评估重组α1-微球蛋白(rA1M)对177Lu-奥曲肽生物动力学与疗效的影响。结果显示rA1M未显著改变177Lu分布,也未显著影响肿瘤疗效,提示其可能作为肾脏保护剂用于神经内分泌肿瘤的177Lu-奥曲肽治疗。

要点

  • rA1M与177Lu-奥曲肽共注射未显著改变小鼠体内177Lu分布。
  • rA1M未显著影响177Lu-奥曲肽对GOT1肿瘤的治疗反应。
  • rA1M有望作为177Lu-奥曲肽治疗中的肾脏保护剂。

核心结论

  • rA1M与177Lu-奥曲肽联用未对肿瘤吸收剂量或治疗反应产生负面影响,可能是有前景的肾脏保护剂。

研究设计与样本

  • 在GOT2荷瘤BALB/c裸鼠中比较177Lu-奥曲肽单独或与rA1M共注射后1-168小时的生物分布。
  • 在GOT1荷瘤BALB/c裸鼠中设rA1M组、177Lu-奥曲肽组、联合组及未治疗对照组,测量肿瘤体积观察疗效。

主要发现

  • 177Lu-奥曲肽组与共注射rA1M组之间177Lu生物分布无统计学显著差异。
  • 177Lu-奥曲肽组和联合组在治疗后前2周平均肿瘤体积下降,随后肿瘤再生长。
  • 各组间治疗反应无统计学显著差异。

临床怎么用

  • 在177Lu-奥曲肽治疗神经内分泌肿瘤时,可考虑联用rA1M以保护肾脏而不影响肿瘤疗效。

局限性

  • 研究仅为小鼠肿瘤模型,尚未在患者中验证。
  • 原文未报告rA1M对肾脏保护作用的具体定量结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of neuroendocrine tumors with 177Lu-octreotate results in prolonged survival and improved quality of life for the patient. However, the treatment is today limited by side effects on kidney and bone marrow, and complete tumor remission is rarely seen. A possible way to minimize dose-limiting toxicity and to optimize this treatment method is to use radioprotectors in conjunction with radiotherapy. A recombinant form of α1-microglobulin (rA1M) was recently shown to preserve kidney structure and function after 177Lu-octreotate injection in mice and was suggested as a radioprotector in peptide receptor radionuclide therapy. The aims of this work were to investigate the influence of rA1M on the in vivo biokinetics of 177Lu-octreotate, with a focus on tumor tissue, and to study the impact of rA1M on the therapeutic response in tumor tissue subjected to 177Lu-octreotate treatment. Methods: The biodistribution of 177Lu-octreotate was examined in BALB/c nude mice with GOT2 tumors 1-168 h after injection with either 177Lu-octreotate or coadministration of 177Lu-octreotate and rA1M. The effects of rA1M on the tumor response after 177Lu-octreotate treatment were studied in BALB/c nude mice with GOT1 tumors. Three groups of mice were administered rA1M, 177Lu-octreotate, or both. Another group served as untreated controls. Tumor volume was measured to follow the treatment effects. Results: No statistically significant difference in biodistribution of 177Lu was observed between the groups receiving 177Lu-octreotate or coinjection of 177Lu-octreotate and rA1M. The therapy study showed a decrease in mean tumor volume during the first 2 wk for both the 177Lu-octreotate group and the coadministration group, followed by tumor regrowth. No statistically significant difference between the groups was found. Conclusion: rA1M did not negatively impact absorbed dose to tumor or therapeutic response in combination with 177Lu-octreotate and may be a promising kidney protector during 177Lu-octreotate treatment of patients with neuroendocrine tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Andersson CK, Shubbar E, Schüler E, et al. Recombinant α1-Microglobulin Is a Potential Kidney Protector in 177Lu-Octreotate Treatment of Neuroendocrine Tumors. J Nucl Med. 2019. PMID: 30926650. doi:10.2967/jnumed.118.225243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。